Results 101 to 110 of about 2,266 (198)

Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐CD73/anti‐PD‐L1 immunotherapy in arm A of the NSGO‐OV‐UMB1/ENGOT‐OV30 trial

Molecular Oncology, EarlyView.
Using mass cytometry, we analyzed serial blood samples from patients with relapsed epithelial ovarian cancer (EOC) treated with oleclumab–durvalumab combination immunotherapy in the NSGO‐OV‐UMB1/ENGOT‐OV30 trial. Our analysis identified potential predictive, monitoring, and response biomarkers detectable through liquid biopsy. These findings facilitate
Luka Tandaric, Annika Auranen, Katrin Kleinmanns, René DePont Christensen, Liv Cecilie Vestrheim Thomsen, Cara Ellen Wogsland, Emmet McCormack, Johanna Mäenpää, Kristine Madsen, Karen Stampe Petersson, Mansoor Raza Mirza, Line Bjørge   +11 more
wiley   +1 more source

Comment on ‘Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results’ [PDF]

, 2015
Vivek Pravin Dave
openalex   +1 more source

Early optical coherence tomography biomarkers for tailored frequency of intravitreal aflibercept in neovascular age-related macular degeneration

Scientific Reports
Intravitreal anti-vascular endothelial growth factor (VEGF) injections are essential for treating neovascular age-related macular degeneration (nAMD), but patient responses vary significantly, complicating standardized regimens.
Gyeongsoo Lim, Kyung Tae Kim, Dong Yoon Kim, Ju Byung Chae, Eoi Jong Seo   +4 more
doaj   +1 more source

Analysis of comprehensive genomic profiling of solid tumors with a novel assay for broad analysis in clinical diagnostics

Molecular Oncology, EarlyView.
In molecular cancer diagnostics, comprehensive genomic profiling (CGP) is going to replace the small NGS panels since it provides all clinically relevant somatic variants as well as genomic biomarkers with clinical value. Here, we compared two CGP assays and demonstrate that the choice for diagnostic implementation will depend on the specific ...
Guy Froyen, Pieter‐Jan Volders, Ellen Geerdens, Severine Berden, Joni Van der Meulen, Aaron De Cock, Stefanie Vermeire, Jacques Van Huysse, Marie de Barsy, Gabriela Beniuga, Wendy W. J. de Leng, Anne M. L. Jansen, Imke Demers, Zeliha Ozgur, Hendrikus Jan Dubbink, Ernst‐Jan M. Speel, Wilfred F. J. van IJcken, Brigitte Maes   +17 more
wiley   +1 more source

Extended Follow-up of Late Toxicity in a Large Cohort of Prostate Cancer Patients Treated With Definitive External Beam Radiation Therapy [PDF]

, 2015
Sean McBride, I. Iamundo De Cumis, Marisa Kollmeier, Xin Pei, Michael J. Zeléfsky   +4 more
openalex   +1 more source

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration

Clinical Ophthalmology, 2019
Justus G Garweg1,21Swiss Eye Institute, Rotkreuz, and Berner Augenklinik Am Lindenhofspital, Bern, Switzerland; 2Department of Ophthalmology, Inselspital, University of Bern, Bern, SwitzerlandPurpose: To review published evidence for a treatment interval
Garweg JG
doaj  

Aflibercept for central retinal vein occlusions: long-term outcomes of a ‘Treat-and-Extend’ regimen

BMJ Open Ophthalmology
Background/aims This study reports on the long-term functional and anatomical outcomes of patients with central retinal vein occlusion (CRVO) treated under the Bern treat-and-extend (T&E) protocol.Methods Observational study. Treatment-naive patients
Sebastian Wolf, Damian Jaggi, Thanoosha Nagamany, Martin S. Zinkernagel, Florian M. Heussen   +4 more
doaj   +1 more source

Response to neoadjuvant chemotherapy in early breast cancers is associated with epithelial–mesenchymal transition and tumor‐infiltrating lymphocytes

Molecular Oncology, EarlyView.
Epithelial–mesenchymal transition (EMT) and tumor‐infiltrating lymphocytes (TILs) are associated with early breast cancer response to neoadjuvant chemotherapy (NAC). This study evaluated EMT and TIL shifts, with immunofluorescence and RNA sequencing, at diagnosis and in residual tumors as potential biomarkers associated with treatment response.
Françoise Derouane, Jérôme Ambroise, Cédric van Marcke, Mieke Van Bockstal, Martine Berlière, Christine Galant, Hélène Dano, Médina Lougué, Elena Benidovskaya, Guy Jerusalem, Vincent Bours, Claire Josse, Jérôme Thiry, Aurélie Daumerie, Caroline Bouzin, Cyril Corbet, François P. Duhoux   +16 more
wiley   +1 more source

Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study [PDF]

, 2016
Antoine Dürrbach, José Medina‐Pestana, Sander Florman, María del Carmen Rial, Lionel Rostaing, Dirk Kuypers, Arthur J. Matas, Thomas Wekerle, Martin S. Polinsky, H.-U. Meier-Kriesche, Stéphane Munier, Josep M. Grinyó   +11 more
openalex   +1 more source

Molecular and functional profiling unravels targetable vulnerabilities in colorectal cancer

Molecular Oncology, EarlyView.
We used whole exome and RNA‐sequencing to profile divergent genomic and transcriptomic landscapes of microsatellite stable (MSS) and microsatellite instable (MSI) colorectal cancer. Alterations were classified using a computational score for integrative cancer variant annotation and prioritization.
Efstathios‐Iason Vlachavas, Konstantinos Voutetakis, Vivian Kosmidou, Spyridon Tsikalakis, Spyridon Roditis, Konstantinos Pateas, Ryangguk Kim, Kymberleigh Pagel, Stephan Wolf, Gregor Warsow, Antonia Dimitrakopoulou‐Strauss, Georgios N. Zografos, Alexander Pintzas, Johannes Betge, Olga Papadodima, Stefan Wiemann   +15 more
wiley   +1 more source